Adamas provides program update for ads-5102 for multiple sclerosis patients with walking impairment

Adamas provides program update for ads-5102 for multiple sclerosis patients with walking impairment.adamas pharmaceuticals inc - completion of its evaluation of ads-5102 in multiple sclerosis patients with walking impairment.adamas pharmaceuticals inc - reconfirms it will not initiate further phase 3 development in msw..adamas pharma - co's engagement with fda to understand potential path to submission confirmed need for additional phase 3 confirmatory study.
ADMS Ratings Summary
ADMS Quant Ranking